Covid-19 test backlogs stemming from lab supply manufacturing snags are expected to continue despite the billions of dollars Congress is pumping into testing programs.
Part of the $48.7 billion that Congress set aside for testing and contact tracing under the latest Covid-19 relief law will likely go toward domestic production of pipette tips and other supplies that have been difficult to get during the pandemic. But even with the extra funds, there’s still a limited number of companies with the expertise and capacity to make those products, lab officials and supply chain consultants say.
“Money can’t buy more of stuff ...